290 related articles for article (PubMed ID: 8579049)
1. Cytomegalovirus surveillance and prevention in allogeneic bone marrow transplantation: examination of a preemptive plan of ganciclovir therapy.
Mandanas RA; Saez RA; Selby GB; Confer DL
Am J Hematol; 1996 Feb; 51(2):104-11. PubMed ID: 8579049
[TBL] [Abstract][Full Text] [Related]
2. Preemptive ganciclovir administration based solely on asymptomatic pulmonary cytomegalovirus infection in allogeneic bone marrow transplant recipients: long-term follow-up.
Zaia JA; Schmidt GM; Chao NJ; Rizk NW; Nademanee AP; Niland JC; Horak DA; Lee J; Gallez-Hawkins G; Kusnierz-Glaz CR
Biol Blood Marrow Transplant; 1995 Dec; 1(2):88-93. PubMed ID: 9118297
[TBL] [Abstract][Full Text] [Related]
3. A randomised trial comparing cytomegalovirus antigenemia assay vs screening bronchoscopy for the early detection and prevention of disease in allogeneic bone marrow and peripheral blood stem cell transplant recipients.
Humar A; Lipton J; Welsh S; Moussa G; Messner H; Mazzulli T
Bone Marrow Transplant; 2001 Sep; 28(5):485-90. PubMed ID: 11593322
[TBL] [Abstract][Full Text] [Related]
4. Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV infection.
Einsele H; Hebart H; Kauffmann-Schneider C; Sinzger C; Jahn G; Bader P; Klingebiel T; Dietz K; Löffler J; Bokemeyer C; Müller CA; Kanz L
Bone Marrow Transplant; 2000 Apr; 25(7):757-63. PubMed ID: 10745262
[TBL] [Abstract][Full Text] [Related]
5. Ganciclovir prophylaxis for cytomegalovirus infection in pediatric allogeneic bone marrow transplant recipients.
Canpolat C; Culbert S; Gardner M; Whimbey E; Tarrand J; Chan KW
Bone Marrow Transplant; 1996 Apr; 17(4):589-93. PubMed ID: 8722360
[TBL] [Abstract][Full Text] [Related]
6. Comparison of cytomegalovirus antigenemia and shell vial culture in allogeneic marrow transplantation recipients receiving ganciclovir prophylaxis.
Nicholson VA; Whimbey E; Champlin R; Abi-Said D; Przepiorka D; Tarrand J; Chan K; Bodey GP; Goodrich JM
Bone Marrow Transplant; 1997 Jan; 19(1):37-41. PubMed ID: 9012929
[TBL] [Abstract][Full Text] [Related]
7. Prophylactic ganciclovir is more effective in HLA-identical family member marrow transplant recipients than in more heavily immune-suppressed HLA-identical unrelated donor marrow transplant recipients. Australasian Bone Marrow Transplant Study Group.
Atkinson K; Arthur C; Bradstock K; Dale B; Downs K; Gibson J; Golenia M; Ho J; Joshua D; Juttner C
Bone Marrow Transplant; 1995 Sep; 16(3):401-5. PubMed ID: 8535313
[TBL] [Abstract][Full Text] [Related]
8. Risk-adapted pre-emptive therapy for cytomegalovirus disease in patients undergoing allogeneic bone marrow transplantation.
Mori T; Okamoto S; Matsuoka S; Yajima T; Wakui M; Watanabe R; Ishida A; Iwao Y; Mukai M; Hibi T; Ikeda Y
Bone Marrow Transplant; 2000 Apr; 25(7):765-9. PubMed ID: 10745263
[TBL] [Abstract][Full Text] [Related]
9. Randomized clinical trial of ganciclovir vs acyclovir for prevention of cytomegalovirus antigenemia after allogeneic transplantation.
Burns LJ; Miller W; Kandaswamy C; DeFor TE; MacMillan ML; Van Burik JA; Weisdorf DJ
Bone Marrow Transplant; 2002 Dec; 30(12):945-51. PubMed ID: 12476289
[TBL] [Abstract][Full Text] [Related]
10. Late cytomegalovirus pneumonia in adult allogeneic blood and marrow transplant recipients.
Nguyen Q; Champlin R; Giralt S; Rolston K; Raad I; Jacobson K; Ippoliti C; Hecht D; Tarrand J; Luna M; Whimbey E
Clin Infect Dis; 1999 Mar; 28(3):618-23. PubMed ID: 10194088
[TBL] [Abstract][Full Text] [Related]
11. Randomized comparison of oral valacyclovir and intravenous ganciclovir for prevention of cytomegalovirus disease after allogeneic bone marrow transplantation.
Winston DJ; Yeager AM; Chandrasekar PH; Snydman DR; Petersen FB; Territo MC;
Clin Infect Dis; 2003 Mar; 36(6):749-58. PubMed ID: 12627359
[TBL] [Abstract][Full Text] [Related]
12. [Ganciclovir prophylaxis for cytomegalovirus interstitial pneumonitis after allogeneic bone marrow transplantation].
Sakai R; Maruta A; Taguchi J; Tomita N; Fujita H; Kodama F; Ogawa K; Fujisawa S; Matsuzaki M; Motomura S; Okubo T
Rinsho Ketsueki; 1996 Jan; 37(1):14-21. PubMed ID: 8683862
[TBL] [Abstract][Full Text] [Related]
13. Preemptive therapy with intravenous ganciclovir for the prevention of cytomegalovirus disease in lung transplant recipients.
Monforte V; Román A; Gavaldà J; Bravo C; Gispert P; Pahissa A; Morell F
Transplant Proc; 2005 Nov; 37(9):4039-42. PubMed ID: 16386621
[TBL] [Abstract][Full Text] [Related]
14. The clinical utility of CMV surveillance cultures and antigenemia following bone marrow transplantation.
Humar A; O'Rourke K; Lipton J; Messner H; Meharchand J; Mahony J; Walker I; Wasi P; McGeer A; Moussa G; Chua R; Mazzulli T
Bone Marrow Transplant; 1999 Jan; 23(1):45-51. PubMed ID: 10037050
[TBL] [Abstract][Full Text] [Related]
15. [Effectiveness of preemptive therapy with ganciclovir in recipients of renal transplants at high risk (R-/D+) for the development of cytomegalovirus disease].
Aranda-Verástegui F; Alberú J; Soto-Ramírez LE; González-Aguirre H; Muñoz Trejo T; Mancilla E; Díliz H; Correa-Rotter R; Sierra-Madero J
Rev Invest Clin; 2002; 54(3):198-203. PubMed ID: 12183888
[TBL] [Abstract][Full Text] [Related]
16. A pilot phase II study of alternate day ganciclovir and foscarnet in preventing cytomegalovirus (CMV) infections in at-risk pediatric and adolescent allogeneic stem cell transplant recipients.
Shereck EB; Cooney E; van de Ven C; Della-Lotta P; Cairo MS
Pediatr Blood Cancer; 2007 Sep; 49(3):306-12. PubMed ID: 16972242
[TBL] [Abstract][Full Text] [Related]
17. Prophylactic use of ganciclovir for allogeneic bone marrow transplant recipients.
von Bueltzingsloewen A; Bordigoni P; Witz F; Bene MC; Schmitt C; Lacour B; Sommelet D
Bone Marrow Transplant; 1993 Sep; 12(3):197-202. PubMed ID: 8241976
[TBL] [Abstract][Full Text] [Related]
18. Pre-emptive ganciclovir treatment can play a role in restoration of hematopoiesis after allogeneic bone marrow transplantation.
Choi JH; Kim DW; Cho SG; Yoo JH; Jeong DC; Han CW; Shin WS; Min WS; Kim HK; Kim CC; Kim DJ
Bone Marrow Transplant; 1997 Jan; 19(2):187-90. PubMed ID: 9116619
[TBL] [Abstract][Full Text] [Related]
19. Foscarnet for prevention of cytomegalovirus infection in allogeneic marrow transplant recipients unable to receive ganciclovir.
Ippoliti C; Morgan A; Warkentin D; van Besien K; Mehra R; Khouri I; Giralt S; Gajewski J; Champlin R; Andersson B; Przepiorka D
Bone Marrow Transplant; 1997 Sep; 20(6):491-5. PubMed ID: 9313883
[TBL] [Abstract][Full Text] [Related]
20. Ganciclovir three times per week is not adequate to prevent cytomegalovirus reactivation after T cell-depleted marrow transplantation.
Przepiorka D; Ippoliti C; Panina A; Goodrich J; Giralt S; van Besien K; Mehra R; Deisseroth AB; Andersson B; Luna M
Bone Marrow Transplant; 1994 Apr; 13(4):461-4. PubMed ID: 8019472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
